BR112012022552A8 - uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos - Google Patents

uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos

Info

Publication number
BR112012022552A8
BR112012022552A8 BR112012022552A BR112012022552A BR112012022552A8 BR 112012022552 A8 BR112012022552 A8 BR 112012022552A8 BR 112012022552 A BR112012022552 A BR 112012022552A BR 112012022552 A BR112012022552 A BR 112012022552A BR 112012022552 A8 BR112012022552 A8 BR 112012022552A8
Authority
BR
Brazil
Prior art keywords
fenoterol
treatment
analogs
gliobastomas
astrocytomas
Prior art date
Application number
BR112012022552A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012022552A2 (pt
Inventor
W Wainer Irving
Robert Toll Lawrence
Arenas Jimenez Lucita
Bernier Michael
Original Assignee
Stanford Res Inst Int
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Res Inst Int, Us Health filed Critical Stanford Res Inst Int
Publication of BR112012022552A2 publication Critical patent/BR112012022552A2/pt
Publication of BR112012022552A8 publication Critical patent/BR112012022552A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012022552A 2010-03-10 2011-03-10 uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos BR112012022552A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31264210P 2010-03-10 2010-03-10
PCT/US2011/027988 WO2011112867A1 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Publications (2)

Publication Number Publication Date
BR112012022552A2 BR112012022552A2 (pt) 2016-08-30
BR112012022552A8 true BR112012022552A8 (pt) 2017-12-05

Family

ID=43858307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022552A BR112012022552A8 (pt) 2010-03-10 2011-03-10 uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos

Country Status (7)

Country Link
US (4) US9492405B2 (https=)
EP (1) EP2544676B1 (https=)
JP (1) JP5837890B2 (https=)
AU (2) AU2011224241B2 (https=)
BR (1) BR112012022552A8 (https=)
CA (1) CA2791702C (https=)
WO (1) WO2011112867A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177418A1 (en) 2012-05-25 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
US20170172944A1 (en) * 2014-04-03 2017-06-22 Mitchell Woods Pharmaceuticals, Inc. Methods of treating melanoma
WO2015153719A2 (en) * 2014-04-03 2015-10-08 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
KR101585619B1 (ko) * 2014-11-20 2016-01-15 주식회사 아모텍 감전보호소자 및 이를 구비한 휴대용 전자장치
WO2016144371A1 (en) * 2015-03-06 2016-09-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
WO2017070052A1 (en) * 2015-10-18 2017-04-27 Onco Therapies Llc Compositions and methods of regulating cancer related disorders and diseases
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN114456078B (zh) * 2022-01-19 2022-09-16 汉瑞药业(荆门)有限公司 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296701A (https=)
SE354279B (https=) 1969-06-13 1973-03-05 Draco Ab
CH564509A5 (https=) 1969-12-12 1975-07-31 Boehringer Sohn Ingelheim
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
DE2010883A1 (de) 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194B2 (https=) 1973-08-10 1978-01-26
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
CA2130578A1 (en) 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
WO1998001099A2 (en) 1996-07-05 1998-01-15 E.C. Pesterfield Assoc., Inc. Method of treating retinal ischemia and glaucoma
US6015837A (en) 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
AU9672598A (en) 1997-09-30 1999-04-23 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
AU6167599A (en) 1998-09-30 2000-04-17 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of a beta2 adrenergic receptor agonist in the treatment of cardiovascular disease
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
WO2003099764A1 (en) 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050107417A1 (en) 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
ATE407925T1 (de) 2003-11-03 2008-09-15 Myogen Inc 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
JP2007530566A (ja) 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
EP1781331A1 (en) 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
NZ556335A (en) 2005-01-11 2009-07-31 Glaxo Group Ltd Cinnamate salts of a beta-2 adrenergic agonist
WO2008022038A1 (en) * 2006-08-10 2008-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
JP5546455B2 (ja) 2007-10-02 2014-07-09 リグスホスピタル 交感神経系α‐および／またはβ‐アドレナリン受容体に対してアゴニスト作用を有する交感神経作動薬の血餅強度改善に関連した全身的止血促進効果
EP2515946B1 (en) * 2009-12-23 2019-05-22 The Board of Trustees of the University of Illionis Nanoconjugates and nanoconjugate formulations

Also Published As

Publication number Publication date
US10130594B2 (en) 2018-11-20
CA2791702C (en) 2018-05-29
EP2544676B1 (en) 2018-09-19
AU2011224241B2 (en) 2014-05-08
WO2011112867A8 (en) 2012-09-27
AU2014210656B2 (en) 2016-03-17
US9492405B2 (en) 2016-11-15
US20200197332A1 (en) 2020-06-25
CA2791702A1 (en) 2011-09-15
AU2014210656A1 (en) 2014-08-28
JP5837890B2 (ja) 2015-12-24
WO2011112867A1 (en) 2011-09-15
US20130005799A1 (en) 2013-01-03
US10617654B2 (en) 2020-04-14
US20170007556A1 (en) 2017-01-12
US10925840B2 (en) 2021-02-23
US20190008802A1 (en) 2019-01-10
EP2544676A1 (en) 2013-01-16
BR112012022552A2 (pt) 2016-08-30
JP2013522230A (ja) 2013-06-13
AU2011224241A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
IN2015DN03219A (https=)
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
BR112015008487A2 (pt) compostos de benzeno substituído
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112012021275A2 (pt) composição, formulação, e, uso de uma formulação.
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
CL2010001174A1 (es) Uso de espironolactona, sus polimorfos, hidratos o solvatos para preparar un medicamento util para prevenir y/o tratar la esclerosis muiltiple.
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2822 DE 04/02/2025.